Characteristics of included studies and their participants with IPF
| Investigators | N | Modality of IPF diagnosis | Mean (SD)years since diagnosis | Mean (SD)age(years) | % Male | Mean (SD)FVC% | Mean (SD) Tlco% | Mean Pao2at rest(kPa) | Taking oral medication for IPF at time of study (%) | Using supplementary oxygen at time of study (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| FVC, forced vital capacity; Tlco, carbon monoxide transfer factor; Pao2, arterial oxygen tension. | ||||||||||
| *Duration of symptoms rather than time since diagnosis. | ||||||||||
| †Slow vital capacity. | ||||||||||
| NR = not reported. | ||||||||||
| Numbers in parentheses are standard deviation (SD) and are reported where available. | ||||||||||
| De Vries19 | 10 | NR | NR | 61.1 (11.6) | 40 | NR | 48.4 (12.2) | 9.3 | 60 | 10 |
| Martinez21 | 34 | 27 biopsy proven IPF | NR | 58.3 (10.9) | 62.4 (3) | NR | 8.9 (0.3) | 100 | 3 | |
| 7 clinical IPF | 59 | |||||||||
| De Vries20 | 41 | 41 biopsy proven IPF | 5.8 (5.4) | 63.5 | 37 | NR | 45.3 (14.9) | 9.1 | 68 | 34 |
| Martinez22 | 30 | 25 biopsy proven IPF | NR | 58.6 (2.0) | 60 | 61.9 (3.2) | NR | 8.7 (0.3) | 100 | NR |
| 5 clinical IPF | ||||||||||
| Nishiyama16 | 41 | 21 biopsy proven IPF | NR | 64 (9) | 85 | 76.6 (16.8)† | 58.9 (20.4) | 11.1 | 0 | 0 |
| Douglas23 | 26 | 1 biopsy proven IPF | 3* | 68 | 77 | 64 | 50 | NR | 0 | NR |
| 25 clinical IPF | ||||||||||
| Raghu24 | 330 | 213 biopsy proven IPF | 1.1 | 64 | 69 | 64 | 37 | 9.9 | 76 | 36 |
| 117 clinical IPF | ||||||||||